In a bid to diversify its product portfolio, Assertio has agreed to acquire Spectrum Pharmaceuticals for US$291 M. Through the deal, Assertio will gain access to Spectrum’s marketed product, Rolvendon™(eflapegrastim-xnst), for the treatment of neutropenia as well as pipeline asset, poziotinib, for the treatment of patients with previously treated locally advanced or metastatic non-small cell lung cancer. Interestingly, the takeover comes five months after Spectrum received a CRL from the FDA for poziotinib.